Cart
sales@molnova.com
D-alpha-Methylbenzyl isothiocyanate
CAS No. 24277-44-9
D-alpha-Methylbenzyl isothiocyanate( —— )
Catalog No. M27150 CAS No. 24277-44-9
D-alpha-Methylbenzyl isothiocyanate, an antioxidant and a chiral agent, induces phase II enzyme activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 45 | Get Quote |
|
| 10MG | 68 | Get Quote |
|
| 25MG | 115 | Get Quote |
|
| 50MG | 173 | Get Quote |
|
| 100MG | 258 | Get Quote |
|
| 200MG | 388 | Get Quote |
|
| 500MG | 642 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameD-alpha-Methylbenzyl isothiocyanate
-
NoteResearch use only, not for human use.
-
Brief DescriptionD-alpha-Methylbenzyl isothiocyanate, an antioxidant and a chiral agent, induces phase II enzyme activity.
-
DescriptionD-alpha-Methylbenzyl isothiocyanate, an antioxidant and a chiral agent, induces phase II enzyme activity.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptorα4β2 nAChR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number24277-44-9
-
Formula Weight163.24
-
Molecular FormulaC9H9NS
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC[C@@H](N=C=S)c1ccccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Ramakrishna Nirogi, et al. Discovery and Development of 3-(6-Chloropyridine-3-yloxymethyl)-2-azabicyclo[3.1.0]hexane Hydrochloride (SUVN-911): A Novel, Potent, Selective, and Orally Active Neuronal Nicotinic Acetylcholine α4β2 Receptor Antagonist for the Treatment of Depression. J Med Chem. 2020 Mar 26;63(6):2833-2853.
molnova catalog
related products
-
Ald-Ph-NHS ester
Ald-Ph-NHS ester is a nonclaevable linker for antibody-drug-conjugation (ADC).
-
trans-Benzylideneace...
trans-4-Phenyl-3-buten-2-one is used in various synthetic preparations.
-
APOL1-IN-1
APOL1-IN-1 is a potent inhibitor of apolipoprotein L1 (APOL1) that can be used to study the pathogenesis of focal segmental glomerulosclerosis (FSGS) and nondiabetic kidney disease (NDKD), facilitating research into these diseases.
